300357SZSE

Announcement on the Approval of the Supplementary Application for Clinical Trials of Dog Dander Skin Prick Liquid

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.·February 27, 2026

✨ AI Summary

Zhejiang WoBio Technology Co., Ltd. has received approval from the National Medical Products Administration for a supplementary application for clinical trials of its dog dander skin prick liquid. The approved product will include new specifications of 39000DU/ml and 19500DU/ml. The company plans to conduct Phase III clinical trials and will disclose further developments in a timely manner.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Basic Information

Drug Name: Dog Dander Skin Prick Liquid
Registration Category: Therapeutic Biological Product
Dosage Form: Skin prick reagent
Indication: Used for skin prick tests to assist in diagnosing Type I hypersensitivity diseases related to dog dander.
Drug Registration Applicant: Zhejiang WoBio Technology Co., Ltd.

According to the Drug Administration Law of the People's Republic of China and relevant regulations, the supplementary application for the clinical trial of this product has been approved. The clinical trial will continue as per the approved content.

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.